Based on these numbers I can't see how another cap raising after...

Based on these numbers I can't see how another cap raising after the consolidation is even viable. What have we got that will produce the revenue needed to sustain the business, even through next year? Why would anyone invest? The total lack of any progress with Eddingpharm and TEVA suggest royalties and manufacturing revenue is a pipe dream. I think the best and most likely strategy is a sale to, or merger with, a company that has a sustainable revenue stream and can develop the so called jewels long term. I also ask why would any talented and dynamic MD take on this basket case? They would need a considerable salary to justify the risk. A salary the company cannot afford.